Encapsulation in hollow fibres of xenogeneic cells engineered to secrete IL-4 or IL-13 ameliorates murine collagen-induced arthritis (CIA)

Clinical and Experimental Immunology

Volumn 117, Issue 2, 1999, Pages 376-382

  Bessis, N ^a,b   Honiger, J ^c   Damotte, D ^d   Minty, A ^e   Fournier, C ^f   Fradelizi, D ^b   Boissier, Marie Christophe ^a,b,f  

^a UNIVERSITÉ PARIS 13   (France)

^b INSERM   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e SANOFI   (France)

^f AVICENNE HOSPITAL   (France)

Author keywords

Collagen arthritis; Gene therapy; IL 4; Immunoisolation; Rheumatoid arthritis

Indexed keywords

COLLAGEN; COPOLYMER; RECOMBINANT INTERLEUKIN 13; RECOMBINANT INTERLEUKIN 4;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; BIOCOMPATIBILITY; CHO CELL; CONTROLLED STUDY; GENE THERAPY; GENETIC ENGINEERING; HISTOLOGY; HOLLOW FIBER MEMBRANE; HYDROGEL; MICROENCAPSULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ACRYLIC RESINS; ACRYLONITRILE; ANIMALS; ARTHRITIS, EXPERIMENTAL; CHO CELLS; CRICETINAE; GENE THERAPY; HELA CELLS; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4; MALE; MEMBRANES, ARTIFICIAL; MICE; MICE, INBRED DBA; MICE, NUDE; NEOPLASM TRANSPLANTATION; PERMEABILITY; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0032839668     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00959.x     Document Type: Article

References (41)

1. 1 Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995; 38:151-60.
2. 2 Brennan FM, Gibbons DL, Mitchell T, Cope AP, Maini RN, Feldman M. Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur J Immunol 1992; 22:1907-12.
3. 3 Williams RO, Mason LJ, Feldman M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89:9784-8.
4. 4 Elliot MJ, Maini RN, Feldman M, Mong-Fox A, Charles P, Bijl H, Woody JN. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344:1125-7.
5. 5 Mori L, De Iselin S, Libero G, Lesslauer W. Attenuation of collagen-induced arhritis in 55-KDa TNF receptor type I (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol 1996; 157:3178-82.
6. 6 Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993; 151:6602-7.
7. 7 Wooley PH, Wahlen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, Staite ND. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 1993; 36:1305-14.
8. 8 van den Berg WB, Joosten LAB, Helsen M, van de Loo FAS. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 1994; 95:237-43.
9. 9 Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-type TNF-α, anti-IL-1 α/β, and IL-1 Ra. Arthritis Rheum 1996; 39:797-809.
10. 10 Boissier M-C, Chiocchia G, Bessis N, Hajnal J, Garotta G, Nicoletti F, Fournier C. Biphasic effect of interferon-γ in murine collagen-induced arthritis. Eur J Immunol 1995; 25:1184-9.
11. 11 Manoury-Schwartz B, Chiocchia G, Bessis N et al.. High susceptibility to collagen-induced arthritis in mice lacking IFN-γ receptors. J Immunol 1997; 158:5501-6.
12. 12 Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A, Matthys P. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol 1997; 158:5507-13.
13. 13 Mauritz NJ, Holmdahl R, Jonsson R, Van der Meide PH, Scheynius A, Klareskog L. Treatment with gamma-interferon triggers the onset of collagen arthritis in mice. Arthritis Rheum 1988; 31:1297-304.
14. 14 Nakajima H, Takamori H, Hiyama Y, Tsukada W. The effect of treatment with interferon-gamma on type II collagen-induced arthritis. Clin Exp Immunol 1990; 81:441-5.
15. 15 Mauri C, Williams RO, Walmsley M, Feldman M. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol 1996; 26:1511-8.
16. 16 Don Carli A, Stasiuk L, Fournier C, Abehsira-Amar O. Conversion in vivo from an early dominant Th0/Th1 response to a Th2 phenotype during the development of collagen-induced arthritis. Eur J Immunol 1997; 27:1451-8.
17. 17 Joosten LAB, Lubberts E, Durez P, Helsen MA, Jacobs MJM, Goldman M, van den Berg WB. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Arthritis Rheum 1997; 40:249-60.
18. 18 Horsfall AC, Butler DM, Marinova L, Warden PJ, Williams RO, Maini RN, Feldmann M. Suppression of collagen-induced arthritis by continuous administration of IL-4. J Immunol 1997; 159:5687-96.
19. 19 Bessis N, Boissier M-C, Ferrara P, Blankenstein T, Fradelizi D, Fournier C. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. Eur J Immunol 1996; 26:2399-403.
20. 20 Bessis N, Chiocchia G, Kollias G, Minty A, Fournier C, Fradelizi D, Boissier MC. Modulation of pro-inflammatory cytokine production in TNF-α transgenic mice by treatment with cells engineered to secrete interleukin (IL)-4, IL-10 or IL-13. Clin Exp Immunol 1998; 111:391-6.
21. 21 Bandara G, Muelle GM, Galea-Lauri J et al. Intraarticular expression of biologically active interleukin-1-receptor antagonist protein by ex-vivo gene transfer. Proc Natl Acad Sci USA 1993; 90:10764-8.
22. 22 Baragi VM, Renkiewicz RR, Jordan H, Bonadio J, Hartman JW, Roessler BJ. Transplantation of transduced Chondrocytes protects articular cartilage from interleukin-1-induced extracellular matrix degradation. J Clin Invest 1995; 96:2454-60.
23. 23 Honiger J, Balladur P, Mariani P, Calmus Y, Vaubourdolle M, Delelo R, Capeau J, Nordlinger B. Permeability and biocompatibility of a new hydrogel used for encapsulation of hepatocytes. Biomaterials 1995; 16:753-9.
24. 24 Minty A, Chalon P, Guillemot JC et al. Molecular cloning of the MCP-3 chemokine gene and regulation of its expression. Eur Cytokine Ntw 1993; 4:99-110.
25. 25 Platzer C, Richter K, Uberla K, Hock H, Diamanstein T, Blankenstein K. Interleukin-4-mediated tumor suppression in nude mice involves interferon-γ. Eur J Immunol 1992; 22:1729-33.
26. 26 Honiger J, Darquy S, Reach G, Muscat E, Thomas M, Collier C. Preliminary report on cell encapsulation in a hydrogel made of a biocompatible material, AN-69, for the development of a bioartificial pancreas. Int J Artif Org 1994; 17:46-52.
27. 27 Boissier M-C, Chiocchia G, Ronzière M-C, Herbage D, Fournier C. Arthritogenicity of minor cartilage collagens (type IX and XI) in mice. Arthritis Rheum 1990; 33:1-8.
28. 28 Boissier M-C, Feng XZ, Carlioz A, Roudier R, Fournier C. Experimental auto-immune arthritis in mice: 1. Homologous type II collagen is responsible for self perpetuating chronic polyarthritis. Ann Rheum Dis 1987; 46:691-700.
29. 29 Chandran PKG, Ligget R, Kirkpatrick B. Patient survival on PAN/ AN69 membrane hemodialysis: a ten-year analysis. J Am Soc Nephrol 1993; 4:1199-204.
30. 30 Kessler L, Aprahamian M, Keipes M, Damge C, Pinget M, Poinsot D. Diffusion properties of an artificial membrane used for Langerhans islet encapsulation: an in vitro test. Biomaterials 1992; 19:40-49.
31. 31 Tai IT, Sun AM. Microencapsulation of recombinant cells: a new delivery system for gene therapy. FASEB J 1993; 7:1061-9.
32. 32 Lanza RP, Chick RP. Immunoisolation: at a turning point. Immunol Today 1997; 18:135-9.
33. 33 Lacy PE, Hegre OD, Gerasimidi-Vazeou A, Gentile FT, Dionne KE. Maintenance of normoglycemia in diabetic mice by subcutaneous xenografts of encapsulated islets. Science 1991; 254:1782-4.
34. 34 Nyberg SL, Platt JL, Shirabe K, Payne W, Hu WS, Cerra FB. Immunoprotection of xenocytes in a hollow fiber bioartificial liver. ASAIO J 1992; 38:M463-M467.
35. 35 Scharp DW, Swanson CJ, Olack BJ et al. Protection of encapsulated human islets implanted without immunosuppression in patients with type I or type II diabetes and in non diabetic control subjects. Diabetes 1994; 43:1167-70.
36. 36 Al-Hendy A, Hortelano G, Tannenbaum GS, Chang PL. Correction of the growth defect in dwarf mice with nonautologous microencapsulated myoblasts. An alternate approach to somatic gene therapy. Hum Gene Ther 1995; 6:165-75.
37. 37 Cheng WT, Chen BC, Chiou ST, Chen CM. Use of nonautologous microencapsulated fibroblasts in growth hormone gene therapy to improve growth of midget swine. Hum Gene Ther 1998; 9:1995-2003.
38. 38 Hoffman D, Breakefield XO, Short MP, Aebischer P. Transplantation of a polymer-encapsulated cell line genetically engineered to release NGF. Exp Neurol 1993; 122:100-6.
39. 39 Emerich DF, Winn SR, Hantraye PM et al. Protective effect of encapsulated cells producing neurotrophis factor CNTF in a monkey model of Huntington's disease. Nature 1997; 386:395-9.
40. 40 Brauker J, Frost GH, Dwarki V et al. Sustained expression of high levels of human factor IX from human cells implanted within an immunoisolation device into athymic rodents. Hum Gene Ther 1998; 9:879-88.
41. 41 Aebischer P, Schluep M, Deglon N et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nature Med 1996; 2:696-9.